These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19686730)

  • 1. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
    Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
    Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
    Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron, a highly selective 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
    Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats.
    Smith GA; Breger LS; Lane EL; Dunnett SB
    Neuropharmacology; 2012 Oct; 63(5):818-28. PubMed ID: 22722025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
    Soghomonian JJ
    Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
    Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
    J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.